<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evolocumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evolocumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Evolocumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="103780" href="/d/html/103780.html" rel="external">see "Evolocumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="103781" href="/d/html/103781.html" rel="external">see "Evolocumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F36231672"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Repatha;</li>
<li>Repatha Pushtronex System;</li>
<li>Repatha SureClick</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871992"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Repatha</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F46944089"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antilipemic Agent, PCSK9 Inhibitor</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F34671701"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="355cd99a-0024-4930-8b95-6aee3ac5d71d">Heterozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterozygous familial hypercholesterolemia (HeFH): Note:</b> Should be used as adjunct to diet and other LDL-C lowering therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: SUBQ: 140 mg every 2 weeks <b>or</b> 420 mg once a month. If converting between regimens, the first dose of new regimen should be administered on the day of the next scheduled dose of previous regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32865373','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32865373','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be04224c-8e9d-4248-8315-86a413718095">Homozygous familial hypercholesterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous familial hypercholesterolemia (HoFH):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Should be used in combination with other lipid-lowering therapy (eg, statin therapy, LDL apheresis); overall effectiveness determined by LDLR genotype (LDL receptor function) and variable; evolocumab generally lacks efficacy in patients without any <i>LDLR</i> allele defects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27839699','lexi-content-ref-28215937','lexi-content-ref-29284604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27839699','lexi-content-ref-28215937','lexi-content-ref-29284604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients not receiving apheresis</i>: SUBQ: Initial: 420 mg once a month; after 12 weeks of therapy, if further optimization of clinical response is warranted (eg, further LDL reduction), dosing interval may be increased to every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25282520','lexi-content-ref-28215937','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25282520','lexi-content-ref-28215937','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients receiving LDL apheresis</i>: SUBQ: 420 mg every 2 or 4 weeks; dose should be administered immediately after apheresis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28215937','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28215937','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130517"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥10 years and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51130518"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child Pugh classes A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F34671713"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="103780" href="/d/html/103780.html" rel="external">see "Evolocumab: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cf1be53-8ecc-4afa-ba04-0ea66bf5b771">Atherosclerotic cardiovascular disease, primary or secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atherosclerotic cardiovascular disease, primary or secondary prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May use as an additional agent in patients who do not meet cholesterol treatment goals with dietary modification plus maximally tolerated lipid-lowering therapies (eg, a high-intensity statin and ezetimibe) or as an alternative agent in patients intolerant of such therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461','lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461','lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 140 mg once every 2 weeks or 420 mg once monthly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8acb610a-038d-4f34-80c0-44b96660d8bf">Familial hypercholesterolemia, heterozygous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial hypercholesterolemia, heterozygous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May use as an additional agent in patients who do not meet cholesterol treatment goals with dietary modification plus maximally tolerated lipid-lowering therapies (eg, a high-intensity statin and ezetimibe) or as an alternative agent in patients intolerant of such therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461','lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461','lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 140 mg once every 2 weeks or 420 mg once monthly.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="551e087f-5dc6-4452-8270-47497a3167ae">Familial hypercholesterolemia, homozygous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial hypercholesterolemia, homozygous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May use as an additional agent in patients who do not meet cholesterol treatment goals with dietary modification plus maximally tolerated lipid-lowering therapies (eg, a high-intensity statin and ezetimibe) or as an alternative agent in patients intolerant of such therapies. Treatment should be guided by a lipid specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461','lexi-content-ref-30586774','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461','lexi-content-ref-30586774','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 420 mg once monthly; may increase to 420 mg once every 2 weeks if clinically meaningful response is not achieved in 12 weeks. <b>Note:</b> For patients receiving lipid apheresis, may begin 420 mg once every 2 weeks administered on the day of apheresis after the session is complete.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching regimens: </b>Administer the first dose of the new regimen on the next scheduled day of the prior regimen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose: </b>Administer within 7 days from the missed dose and resume original schedule. If an every-2-week dose is not administered within 7 days, wait until the next dose on the original schedule. If a once-monthly dose is not administered within 7 days, administer the dose and start a new schedule based on this date.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991743"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988713"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh classes A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56848669"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (eg, <b>angioedema</b>, <b>urticaria</b>) have been reported. Additionally, delayed rashes have been documented, including a rash mimicking atopic dermatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31292332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31292332'])">Ref</a></span>) and maculopapular exanthema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34188988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34188988'])">Ref</a></span>). In the FOURIER study, allergic reactions with evolocumab did not differ significantly from placebo (3.1% versus 2.9%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28304224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28304224'])">Ref</a></span>). A pooled safety analysis of over 6,000 patients in double-blind and open-label studies identified hypersensitivity reactions in 3.2% and 5.7% of patients receiving evolocumab, respectively, versus 2.4% and 4.3% of patients receiving control or standard of care, respectively. Most of these reactions were mild in severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28249876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28249876'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">The most common reactions are delayed injection-site reactions, accompanied by <b>bruising</b>, <b>erythema of the skin</b>, swelling at the site, <b>nasopharyngitis</b>, and <b>flu-like symptoms</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30053327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30053327'])">Ref</a></span>). One postmarketing study reported the overall cumulative 5-year risk of injection-site reactions as 7.6%; however, this incidence decreased over years on therapy and infrequently resulted in discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31648705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31648705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions (eg, angioedema, urticaria) are either IgE-mediated (non–dose-related) or related to another non–IgE-mediated mechanism (eg, polysorbate 80 excipient may activate complement). Delayed hypersensitivity reactions, including rashes (eg, maculopapular) are typically T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>). Injection-site reactions have been postulated to occur due to degradation of the polysorbate excipient and local neoantigen formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30055223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30055223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; maculopapular rashes generally occur 1 to several days after initiation of therapy and have been reported following the second dose of evolocumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34188988','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34188988','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between PCSK9 inhibitors is unknown. Evolocumab contains polysorbate 80 as the excipient and alirocumab contains polysorbate 20. In addition to cross-reactivity between the parent drugs, cross-reactivity may occur between the drugs and other monoclonal antibodies and products (eg, vaccines) based on shared polysorbate excipients. Anti-drug antibodies that cross-react with other PCSK9 inhibitors and may also be implicated in injection-site reactions and loss of efficacy are infrequent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31529318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31529318'])">Ref</a></span>). One patient has been described who developed a rash following alirocumab but was subsequently able to tolerate evolocumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stryker.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stryker.2016'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F43721667"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (children, adolescents: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (children, adolescents, adults: 4% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Nasopharyngitis table link" class="lexi-table-link" data-table-id="lexi-content-nasopharyngitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nasopharyngitis')">table 1</a>)</span><span class="table-link" style="display:none;">Nasopharyngitis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nasopharyngitis" frame="border" id="lexi-content-nasopharyngitis" rules="all">
<caption style="text-align:center;">
<b>Evolocumab: Adverse Reaction: Nasopharyngitis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Heterozygous familial hypercholesterolemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">53</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Homozygous familial hypercholesterolemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">33</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cardiovascular outcomes</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">599</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,052</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,224</p></td></tr></tbody></table>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (3%)</p>
<p style="text-indent:0em;margin-left:2em;">Dermatologic: Skin rash (1%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 2</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Evolocumab: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,526</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis (children, adolescents, adults: 3% to 6%), nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (1%)<span class="lexi-table-link-container"> (<a aria-label="Bruise table link" class="lexi-table-link" data-table-id="lexi-content-bruise" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bruise')">table 3</a>)</span><span class="table-link" style="display:none;">Bruise</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bruise" frame="border" id="lexi-content-bruise" rules="all">
<caption style="text-align:center;">
<b>Evolocumab: Adverse Reaction: Bruise</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,052</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,224</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (children, adolescents, adults: 6% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (3% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Injection-Site Reaction table link" class="lexi-table-link" data-table-id="lexi-content-injection-site-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-injection-site-reaction')">table 4</a>)</span><span class="table-link" style="display:none;">Injection-Site Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Injection-Site Reaction" frame="border" id="lexi-content-injection-site-reaction" rules="all">
<caption style="text-align:center;">
<b>Evolocumab: Adverse Reaction: Injection-Site Reaction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">599</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,526</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4%), fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1% to 5%), oropharyngeal pain (children, adolescents: 7%), sinusitis (4%), upper respiratory tract infection (children, adolescents, adults: 6% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema, erythema of skin<span class="lexi-table-link-container"> (<a aria-label="Erythema of Skin table link" class="lexi-table-link" data-table-id="lexi-content-erythema-of-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erythema-of-skin')">table 5</a>)</span><span class="table-link" style="display:none;">Erythema of Skin</span>, urticaria<span class="lexi-table-link-container"> (<a aria-label="Urticaria table link" class="lexi-table-link" data-table-id="lexi-content-urticaria" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urticaria')">table 6</a>)</span><span class="table-link" style="display:none;">Urticaria</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Erythema of Skin" frame="border" id="lexi-content-erythema-of-skin" rules="all">
<caption style="text-align:center;">
<b>Evolocumab: Adverse Reaction: Erythema of Skin</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,526</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urticaria" frame="border" id="lexi-content-urticaria" rules="all">
<caption style="text-align:center;">
<b>Evolocumab: Adverse Reaction: Urticaria</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Evolocumab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">140 mg every 2 weeks or 420 mg once monthly</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Primary hyperlipidemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,651</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,526</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms</p></div>
<div class="block coi drugH1Div" id="F29871558"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Serious hypersensitivity (eg, angioedema) to evolocumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F34671628"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The packaging (needle cap of prefilled syringe and autoinjector) may contain dry natural rubber, which is a derivative of latex.</p></div>
<div class="block foc drugH1Div" id="F36231673"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Repatha SureClick: 140 mg/mL (1 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Repatha Pushtronex System: 420 mg/3.5 mL (3.5 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Repatha: 140 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F36231671"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F45088623"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Repatha SureClick Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg/mL (per mL): $336.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Repatha Pushtronex System Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420MG/3.5ML (per mL): $208.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Repatha Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg/mL (per mL): $336.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871993"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Repatha: 140 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Repatha: 420 mg/3.5 mL (3.5 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614612"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SUBQ: Do not shake. If refrigerated, allow to stand at room temperature for at least 30 minutes (single-use prefilled autoinjector or single-use prefilled syringe) or at least 45 minutes (single-use on-body infusor with prefilled cartridge) prior to use; do not warm with heat or hot water. Administer SUBQ into areas of the abdomen (except for the 2-inch area around the navel), thigh, or upper arm; only use areas that are not tender, bruised, red, or indurated; avoid areas with scars or stretch marks. Rotate the injection site with each injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Single-use infusor with prefilled cartridge: Administer SUBQ over 5 minutes. Administer medication within 5 minutes of inserting cartridge. Do not use if infusor gets wet (contains electronics that should remain dry), or if dropped onto a hard surface (parts that are not visible may be broken). Use in pediatric patients should be under adult supervision.</p>
<p style="text-indent:-2em;margin-left:2em;">Single-use prefilled autoinjector or single-use prefilled syringe: For autoinjector, administer medication within 5 minutes of removing orange cap; injection should take ~15 seconds. For 420 mg (once-monthly) dose, administer 3 separate SUBQ 140 mg injections consecutively within a 30-minute period.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i> Missed doses</i>: Administer within 7 days from the missed dose and resume original schedule. If an every-2-week dose is not administered within 7 days, wait until the next dose on the original schedule. If a once-monthly dose is not administered within 7 days, administer the dose and start a new schedule based on this date.</p></div>
<div class="block adm drugH1Div" id="F34671726"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> For SUBQ administration. Do not shake. If refrigerated, allow to stand at room temperature for at least 30 minutes (single-use prefilled autoinjector or single-use prefilled syringe) or at least 45 minutes (single-use on-body infusor with prefilled cartridge) prior to use (do not warm with heat or hot water). Administer into areas of the abdomen (except for the 2-inch area around the navel), thigh, or upper arm. Avoid administration in areas where skin is tender, bruised, red, indurated, or has scars or stretch marks. Do not coadminister with other injectable drugs at the same injection site. Rotate the injection site with each injection. When using single-use on-body infusor, administer medication within 5 minutes of inserting cartridge; do not use if infusor gets wet.</p>
<p style="text-indent:-2em;margin-left:2em;">420 mg dose: Administer SUBQ over 5 minutes using the single-use infusor with prefilled cartridge <b>or</b> give 3 separate SUBQ 140 mg injections consecutively within a 30-minute period using the single-use prefilled autoinjector or single-use prefilled syringe.</p></div>
<div class="block sts drugH1Div" id="F34671638"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 2°C to 8°C (36°F to 46°F) in the original carton. May also store at room temperature (at 20°C to 25°C [68°F to 77°F]) in the original carton; however, under these conditions, must use within 30 days (discard if not used within 30 days). Protect from direct light and do not expose to temperatures above 25°C (77°F). Do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53571275"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct to other LDL-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL (FDA approved in ages ≥10 years and adults); adjunct to diet and other lipid-lowering therapy for the treatment of heterozygous familial hypercholesterolemia to reduce LDL (HeFH) (FDA approved in ages ≥10 years and adults); risk reduction for myocardial infarction, stroke, and coronary revascularization in patients with established cardiovascular disease (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F45748325"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Evolocumab may be confused with elotuzumab</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F44576019"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F34671632"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F34671620"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Evolocumab is a humanized monoclonal antibody (IgG<sub>2</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy safety study is underway. If evolocumab is administered during pregnancy, health care providers should report exposure to Amgen’s pregnancy safety study (1-800-772-6436).</p></div>
<div class="block mopp drugH1Div" id="F53571274"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Lipid profile (fasting or nonfasting: baseline and periodic with therapy); measure LDL as early as 4 weeks after initiation; for once-monthly dosing measure LDL just prior to the next scheduled dose (response to evolocumab will depend on degree of LDL-receptor function). Monitor for signs/symptoms of hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F34671644"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Evolocumab is a human monoclonal antibody (IgG2 isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9).  PCSK9 binds to the low-density lipoprotein receptors (LDLR) on hepatocyte surfaces to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL; therefore, the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-cholesterol (LDL-C). By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.</p></div>
<div class="block phk drugH1Div" id="F34671657"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Proprotein convertase subtilisin kexin type 9 (PCSK9) suppression: 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: V<sub>d</sub>: ~3.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Nonsaturable proteolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 72%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 11 to 17 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SUBQ: 3 to 4 days.</p></div>
<div class="block phksp drugH1Div" id="F51154119"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild or moderate hepatic impairment, a 20% to 30% lower mean C<sub>max</sub> and 40% to 50% lower mean AUC occurs.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45784050"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Repatha | Repatha Sureclick</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Repatha Sureclick</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Repatha SureClick</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Repatha</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24678979">
<a name="24678979"></a>Blom DJ, Hala T, Bolognese M, et al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. <i>N Engl J Med</i>. 2014;370(19):1809-1819.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/24678979/pubmed" id="24678979" target="_blank">24678979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27839699">
<a name="27839699"></a>France M, Rees A, Datta D, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. <i>Atherosclerosis</i>. 2016;255:128-139. doi: 10.1016/j.atherosclerosis.2016.10.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/27839699/pubmed" id="27839699" target="_blank">27839699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34188988">
<a name="34188988"></a>Ghernautan V, Amini M, Sachmechi I. Maculopapular exanthema after the second dose of evolocumab. <i>Cureus</i>. 2021;13(5):e15249. doi:10.7759/cureus.15249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/34188988/pubmed" id="34188988" target="_blank">34188988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol [published online November 10, 2018]. <i>Circulation</i>. 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30053327">
<a name="30053327"></a>Gürgöze MT, Muller-Hansma AHG, Schreuder MM, Galema-Boers AMH, Boersma E, Roeters van Lennep JE. Adverse events associated with PCSK9 inhibitors: A real-world experience. <i>Clin Pharmacol Ther</i>. 2019;105(2):496-504. doi:10.1002/cpt.1193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/30053327/pubmed" id="30053327" target="_blank">30053327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911072">
<a name="25911072"></a>Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/25911072/pubmed" id="25911072" target="_blank">25911072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31292332">
<a name="31292332"></a>Kanda N, Okajima F. Atopic dermatitis-like rash during evolocumab treatment of familial hypercholesterolemia. <i>J Nippon Med Sch</i>. 2019;86(3):187-190. doi:10.1272/jnms.JNMS.2019_86-309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/31292332/pubmed" id="31292332" target="_blank">31292332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648705">
<a name="31648705"></a>Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. <i>J Am Coll Cardiol</i>. 2019;74(17):2132-2146. doi:10.1016/j.jacc.2019.08.1024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/31648705/pubmed" id="31648705" target="_blank">31648705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol.</i> 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi: 10.1155/2012/985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi: 10.1002/bdrb.20201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25282520">
<a name="25282520"></a>Raal FJ, Honarpour N, Blom DJ, et al; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2015a;385(9965):341-350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/25282520/pubmed" id="25282520" target="_blank">25282520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28215937">
<a name="28215937"></a>Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. <i>Lancet Diabetes Endocrinol</i>. 2017;5(4):280-290. doi:10.1016/S2213-8587(17)30044-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/28215937/pubmed" id="28215937" target="_blank">28215937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25282519">
<a name="25282519"></a>Raal FJ, Stein EA, Dufour R, et al; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2015b;385(9965):331-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/25282519/pubmed" id="25282519" target="_blank">25282519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Repatha.1">
<a name="Repatha.1"></a>Repatha (evolocumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Repatha.2">
<a name="Repatha.2"></a>Repatha (evolocumab) [summary of product characteristics]. Breda, Netherlands: Amgen Europe B.V.; received 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24825642">
<a name="24825642"></a>Robinson JG, Nedergaard BS, Rogers WJ, et al; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. <i>JAMA</i>. 2014;311(18):1870-1882.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/24825642/pubmed" id="24825642" target="_blank">24825642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28304224">
<a name="28304224"></a>Sabatine MS, Giugliano RP, Keech AC, et al: FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. <i>N Engl J Med</i>. 2017;376(18):1713-1722. doi: 10.1056/NEJMoa1615664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/28304224/pubmed" id="28304224" target="_blank">28304224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32865373">
<a name="32865373"></a>Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. <i>N Engl J Med</i>. 2020;383(14):1317-1327. doi:10.1056/NEJMoa2019910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/32865373/pubmed" id="32865373" target="_blank">32865373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30055223">
<a name="30055223"></a>Singh SK, Mahler HC, Hartman C, Stark CA. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? <i>J Pharm Sci</i>. 2018;107(11):2735-2741. doi:10.1016/j.xphs.2018.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/30055223/pubmed" id="30055223" target="_blank">30055223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stryker.2016">
<a name="Stryker.2016"></a>Stryker M, Kane M, Busch R. Lack of cross-reactivity allergy following a switch from alirocumab to evolocumab. <i>Exp Pharm Res J</i>. 2016;2:3. <a href="https://digitalcommons.cedarville.edu/cgi/viewcontent.cgi?article=1009&amp;context=excerpts_in_pharmacy_research_journal" target="_blank">https://digitalcommons.cedarville.edu/cgi/viewcontent.cgi?article=1009&amp;context=excerpts_in_pharmacy_research_journal</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29284604">
<a name="29284604"></a>Thedrez A, Blom DJ, Ramin-Mangata S, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (Low-Density Lipoprotein Receptor): implications for the efficacy of evolocumab. <i>Arterioscler Thromb Vasc Biol</i>. 2018;38(3):592-598. doi:10.1161/ATVBAHA.117.310217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/29284604/pubmed" id="29284604" target="_blank">29284604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28249876">
<a name="28249876"></a>Toth PP, Descamps O, Genest J, et al; PROFICIO Investigators. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. <i>Circulation</i>. 2017;135(19):1819-1831. doi:10.1161/CIRCULATIONAHA.116.025233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/28249876/pubmed" id="28249876" target="_blank">28249876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31529318">
<a name="31529318"></a>Wang EQ, Bukowski JF, Yunis C, et al. Assessing the potential risk of cross-reactivity between anti-bococizumab antibodies and other anti-PCSK9 monoclonal antibodies. <i>BioDrugs</i>. 2019;33(5):571-579. doi:10.1007/s40259-019-00375-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/evolocumab-pediatric-drug-information/abstract-text/31529318/pubmed" id="31529318" target="_blank">31529318</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 129290 Version 44.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
